Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of RC1012 injection to prevent relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
CTR20231592Phase 2Active
- Sponsor
- Ruichuang Biotech
- Start
- Jul 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of RC1012 in acute myeloid leukemia (AML), sponsored by Ruichuang Biotech. Started Jul 2023; status: active.
02
Drugs
RC1012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20231592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231592.